GlassScriptPhysician profile
Cole J Pizzingrilli
NPI 1619210457
$14,436.01
in general payments reported to CMS, 2019-2025
61 companies · $2,845 in 2025
The $2,845 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,598 · 2022: $3,021 · 2023: $2,647 · 2024: $2,325 · 2025: $2,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,816.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,783.53 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,753.62 | 2021-2025 | |
| Novo Nordisk INC | $1,418.47 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $1,168.07 | 2021-2025 | |
| Lilly USA, LLC | $750.78 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $556.42 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.92 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.41 | 2021-2025 | Xifaxan, Trulance |
| Bayer Healthcare Pharmaceuticals INC. | $384.14 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $347.98 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Merck Sharp & Dohme LLC | $307.78 | 2021-2025 | Gardasil 9, Capvaxive, Belsomra |
| Amgen INC. | $302.50 | 2021-2025 | Evenity, Prolia |
| Axsome Therapeutics, INC. | $301.07 | 2022-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $244.74 | 2023-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $239.94 | 2023-2025 | Ingrezza |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cole Pizzingrilli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.